Literature DB >> 23629001

Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras.

Lee Adam Wheeler1, Vladimir Vrbanac, Radiana Trifonova, Michael A Brehm, Adi Gilboa-Geffen, Serah Tanno, Dale L Greiner, Andrew D Luster, Andrew M Tager, Judy Lieberman.   

Abstract

The continued spread of HIV underscores the need to interrupt transmission. One attractive strategy, in the absence of an effective vaccine, is a topical microbicide, but the need for application around the time of sexual intercourse leads to poor patient compliance. Intravaginal (IVAG) application of CD4 aptamer-siRNA chimeras (CD4-AsiCs) targeting the HIV coreceptor CCR5, gag, and vif protected humanized mice from sexual transmission. In non-dividing cells and tissue, RNAi-mediated gene knockdown lasts for several weeks, providing an opportunity for infrequent dosing not temporally linked to sexual intercourse, when compliance is challenging. Here, we investigate the durability of gene knockdown and viral inhibition, protection afforded by CCR5 or HIV gene knockdown on their own, and effectiveness of CD4-AsiCs formulated in a gel in polarized human cervicovaginal explants and in humanized mice. CD4-AsiC-mediated gene knockdown persisted for several weeks. Cell-specific gene knockdown and protection were comparable in a hydroxyethylcellulose gel formulation. CD4-AsiCs against CCR5 or gag/vif performed as well as a cocktail in humanized mice. Transmission was completely blocked by CCR5 CD4-AsiCs applied 2 days before challenge. Significant, but incomplete, protection also occurred when exposure was delayed for 4 or 6 days. CD4-AsiCs targeting gag/vif provided some protection when administered only after exposure. These data suggest that CD4-AsiCs are a promising approach for developing an HIV microbicide.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23629001      PMCID: PMC3702101          DOI: 10.1038/mt.2013.77

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  50 in total

1.  Disease prevalence among women attending a sexually transmitted disease clinic varies with reason for visit.

Authors:  K M Pabst; C A Reichart; C R Knud-Hansen; J N Wasserheit; T C Quinn; K Shah; G Dallabetta; E W Hook
Journal:  Sex Transm Dis       Date:  1992 Mar-Apr       Impact factor: 2.830

2.  Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras.

Authors:  Lee Adam Wheeler; Radiana Trifonova; Vladimir Vrbanac; Emre Basar; Shannon McKernan; Zhan Xu; Edward Seung; Maud Deruaz; Tim Dudek; Jon Ivar Einarsson; Linda Yang; Todd M Allen; Andrew D Luster; Andrew M Tager; Derek M Dykxhoorn; Judy Lieberman
Journal:  J Clin Invest       Date:  2011-05-16       Impact factor: 14.808

3.  A model for personalized in vivo analysis of human immune responsiveness.

Authors:  Hannes Kalscheuer; Nichole Danzl; Takashi Onoe; Ted Faust; Robert Winchester; Robin Goland; Ellen Greenberg; Thomas R Spitzer; David G Savage; Hiroyuki Tahara; Goda Choi; Yong-Guang Yang; Megan Sykes
Journal:  Sci Transl Med       Date:  2012-03-14       Impact factor: 17.956

4.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

5.  Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.

Authors:  Nan Sook Lee; Taikoh Dohjima; Gerhard Bauer; Haitang Li; Ming-Jie Li; Ali Ehsani; Paul Salvaterra; John Rossi
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

Review 6.  Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.

Authors:  Connie Celum; Jared M Baeten
Journal:  Curr Opin Infect Dis       Date:  2012-02       Impact factor: 4.915

7.  T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice.

Authors:  Priti Kumar; Hong-Seok Ban; Sang-Soo Kim; Haoquan Wu; Todd Pearson; Dale L Greiner; Amale Laouar; Jiahong Yao; Viraga Haridas; Katsuyoshi Habiro; Yong-Guang Yang; Ji-Hoon Jeong; Kuen-Yong Lee; Yong-Hee Kim; Sung Wan Kim; Matthias Peipp; Georg H Fey; N Manjunath; Leonard D Shultz; Sang-Kyung Lee; Premlata Shankar
Journal:  Cell       Date:  2008-08-07       Impact factor: 41.582

8.  Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA.

Authors:  Joseph Anderson; Akhil Banerjea; Vicente Planelles; Ramesh Akkina
Journal:  AIDS Res Hum Retroviruses       Date:  2003-08       Impact factor: 2.205

9.  Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages.

Authors:  Erwei Song; Sang-Kyung Lee; Derek M Dykxhoorn; Carl Novina; Dong Zhang; Keith Crawford; Jan Cerny; Phillip A Sharp; Judy Lieberman; N Manjunath; Premlata Shankar
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

Review 10.  Interfering with disease: a progress report on siRNA-based therapeutics.

Authors:  Antonin de Fougerolles; Hans-Peter Vornlocher; John Maraganore; Judy Lieberman
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

View more
  30 in total

Review 1.  Technologies for controlled, local delivery of siRNA.

Authors:  Samantha M Sarett; Christopher E Nelson; Craig L Duvall
Journal:  J Control Release       Date:  2015-11-28       Impact factor: 9.776

Review 2.  Aptamers in HIV research diagnosis and therapy.

Authors:  Jyoti Bala; Srinivasan Chinnapaiyan; Rajib Kumar Dutta; Hoshang Unwalla
Journal:  RNA Biol       Date:  2018-02-12       Impact factor: 4.652

3.  Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells.

Authors:  William H Thiel; Kristina W Thiel; Katie S Flenker; Tom Bair; Adam J Dupuy; James O McNamara; Francis J Miller; Paloma H Giangrande
Journal:  Methods Mol Biol       Date:  2015

Review 4.  Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS.

Authors:  Manjunath N Swamy; Haoquan Wu; Premlata Shankar
Journal:  Adv Drug Deliv Rev       Date:  2016-03-21       Impact factor: 15.470

5.  Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer-siRNA Chimeras in Human Tumor Xenografts.

Authors:  Xiaohua Ni; Yonggang Zhang; Kenji Zennami; Mark Castanares; Amarnath Mukherjee; Raju R Raval; Haoming Zhou; Theodore L DeWeese; Shawn E Lupold
Journal:  Mol Cancer Ther       Date:  2015-10-05       Impact factor: 6.261

Review 6.  Manipulating the in vivo immune response by targeted gene knockdown.

Authors:  Judy Lieberman
Journal:  Curr Opin Immunol       Date:  2015-07-03       Impact factor: 7.486

Review 7.  The delivery of therapeutic oligonucleotides.

Authors:  Rudolph L Juliano
Journal:  Nucleic Acids Res       Date:  2016-04-15       Impact factor: 16.971

Review 8.  Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective.

Authors:  Somayeh Vandghanooni; Morteza Eskandani; Jaleh Barar; Yadollah Omidi
Journal:  J Mol Med (Berl)       Date:  2018-07-28       Impact factor: 4.599

9.  TREX1 Knockdown Induces an Interferon Response to HIV that Delays Viral Infection in Humanized Mice.

Authors:  Lee Adam Wheeler; Radiana T Trifonova; Vladimir Vrbanac; Natasha S Barteneva; Xing Liu; Brooke Bollman; Lauren Onofrey; Sachin Mulik; Shahin Ranjbar; Andrew D Luster; Andrew M Tager; Judy Lieberman
Journal:  Cell Rep       Date:  2016-05-12       Impact factor: 9.423

10.  CD4 aptamer-RORγt shRNA chimera inhibits IL-17 synthesis by human CD4(+) T cells.

Authors:  Pingfang Song; Yuan K Chou; Xiaowei Zhang; Roberto Meza-Romero; Kentaro Yomogida; Gil Benedek; Cong-Qiu Chu
Journal:  Biochem Biophys Res Commun       Date:  2014-09-18       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.